Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer

Abstract Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved. Here, we find anlotinib enhances radi...

Full description

Bibliographic Details
Main Authors: Dong Han, Jiajia Zhang, Yawei Bao, Lei Liu, Ping Wang, Dong Qian
Format: Article
Language:English
Published: Nature Publishing Group 2022-11-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-022-01256-2

Internet

https://doi.org/10.1038/s41420-022-01256-2

Similar Items